World’s First! Chinese Tongji Hospital Successfully Treats Immune-Mediated Necrotizing Myopathy with CAR-T Cells!

🎉🔬✨ World’s First! Chinese Tongji Hospital Successfully Treats Immune-Mediated Necrotizing Myopathy with CAR-T Cells! ✨🔬🎉

PNAS

🌟A groundbreaking achievement in medicine! Immune-Mediated Necrotizing Myopathy

Professor Wang Wei’s team from Tongji Hospital, affiliated with Huazhong University of Science and Technology, has brought unprecedented hope to patients with immune-mediated necrotizing myopathy. 🌟

📅 On January 30th, their research was published in the prestigious journal “Proceedings of the National Academy of Sciences” (PNAS). They utilized CAR-T cells targeting mature B cell antigen (BCMA) for the first time, achieving significant clinical efficacy in treating immune-mediated necrotizing myopathy. This research opens new avenues for treating this condition, marking a historic breakthrough in medicine.

ℹ️ CAR-T cell therapy

is a gene-editing cellular treatment method. Patient’s own T cells are extracted, genetically modified in vitro to possess targeted killing capabilities. These modified CAR-T cells are then reintroduced into the patient’s body to selectively eliminate target cells, bringing about dramatic changes in the disease’s progression.

Tongji

👨‍⚕️ Patient Mr. Deng is a successful case of CAR-T cell therapy. Diagnosed with immune-mediated necrotizing myopathy seven and a half years ago, his condition worsened over time, leaving him bedridden. After receiving CAR-T treatment, his health significantly improved, he successfully entered graduate school for medical studies, achieved full recovery, discontinued all immunosuppressive drugs, and now lives medication-free. This is a remarkable victory! 💪

🌈 What’s even more surprising is that several patients treated with CAR-T cells experienced the regrowth of new B cells approximately one year post-treatment. These new B cells exhibit a completely different phenotype, and pathogenic antibodies in the patients’ bodies completely disappear, achieving a joyful “immune reshaping.”

🌍 This breakthrough research brings hope to autoimmune disease patients worldwide.

Professor Wang Wei’s team’s efforts have paved the way for new treatment approaches, offering a fresh start for patients once deemed untreatable. We look forward to the global adoption of this treatment method, benefiting more patients worldwide. Let’s cheer for this remarkable achievement together! 👏

In addition to lung cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
doctor.huang@globecancer.com,
or click on the
WhatsApp+8613717959070.

The Medical Department will contact you as soon as they receive the reports.🌟

#CARTCellTherapy #ImmuneMediated #NecrotizingMyopathy #MedicalBreakthrough #TongjiHospital #ScientificResearch #MedicalRevolution #HealthHope #myopathy

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.

The Chinese CAR-T therapy achieves a miraculous cure for advanced liver cancer, creating wonders in the field of cellular treatment for solid tumors.🌞🌞

🥰Surviving Against the Odds: A Chinese Doctor’s Journey with Liver Tumor🥰

Zou began his career in 1989 and has dedicated 30 years as an obstetrician-gynecologist, tirelessly working on the frontline of clinical care.

⭐️”One afternoon, I felt excruciating pain in my right shoulder while sitting in the office. It turned out I had three massive tumors on my liver. At that moment, I had no idea that my life had entered a countdown,” recalls Dr. Zou.⭐️

 

⭐️”Dr. Zou is in the advanced stage of liver cancer, with metastasis to the lungs,” urgently declared Prof.Shi as he convened a team of experts to consult on Dr. Zou’s condition.⭐️

 

⭐️ “With conventional treatment, the survival period is typically 3-6 months. Even with surgery, there’s no hope,” stated Prof.Shi.⭐️ Dr. Zou, a doctor himself, continued to ponder work matters, but colleagues and loved ones were tirelessly searching for any possible cure.

 

⭐️”Prof.Shi mentioned this immunotherapy, an antibody treatment,” said Dr. Zou’s wife.⭐️

Antibody therapy, specifically Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T), is a novel precision-targeted treatment for tumors. Using genetic engineering, T-cells are activated and equipped with a guided navigation device called CAR (Chimeric Antigen Receptor), transforming ordinary warriors into super soldiers known as CAR-T cells. These cells specifically recognize and efficiently eliminate tumor cells, achieving the goal of treating malignant tumors.

Fortunately, Dr. Zou’s health indicators perfectly matched the criteria for CAR-T therapy, providing him with a chance to defy death.

 

⭐️”In the early stages, I needed treatment every two weeks. Finally, after five or six sessions, my cancer cells started degenerating and liquefying. By now, the last and originally largest tumor has significantly liquefied and been absorbed,” Dr. Zou said.⭐️

 

⭐️”A miracle happened. We have taken a significant step in overcoming liver cancer in humans,” Prof.Shi added.⭐️

 

As the treatment gradually took effect, Dr. Zou’s health improved, allowing him to resume his daily work. After completing the treatment cycle, Dr. Zou once again donned the white coat, transitioning from patient to doctor.

 

In his heart, a stronger belief in the sincerity towards the medical profession and the health of patients emerged.

 

#SurvivorStories #MedicalMiracle #Inspiration #CancerSurvivor #CARTTherapy #AgainstAllOdds #HealthJourney #BelieveInMiracles #advancedmedicineinchina #chinesemedicine

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰

🥰Chinese CAR-T Therapy: A Beacon of Hope for Lymphoma Patients🥰

🌞In a groundbreaking development, the Hematology Department at Peking Union Medical College Hospital has achieved remarkable treatment outcomes with commercial CAR-T therapy since 2021.

 

🌞Meet Mr. Li, a 59-year-old with a history of hypertension. In September 2019, he noticed swelling in his right elbow, which worsened over three months, prompting concerns. After visits to multiple hospitals, he was diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL). Further consultations revealed additional challenges: the presence of TP53 and MYD88 gene mutations, adding complexity to his case.

 

🌞Local hospitals initiated frontline treatments, utilizing drugs such as cyclophosphamide, prednisone, ibrutinib, and rituximab. While the initial treatment provided relief, it was short-lived. After six months of rest, Mr. Li experienced discomfort in his lower abdomen, leading to a subsequent diagnosis of DLBCL metastasis. Despite second, third, and fourth-line treatments at local hospitals, his condition remained uncontrolled.

 

🌞In December 2021, Mr. Li placed his last hope in the hands of the lymphoma team at Peking Union Medical College Hospital and underwent CAR-T therapy.

On December 27, 2021, the patient underwent a successful single-cell collection, followed by CAR-T cell infusion on January 20, 2022. Post-infusion, all indicators returned to normal, with only transient fever and CAR-T-related neutropenia observed. Targeted treatment promptly addressed these symptoms, leading to their resolution. One month after discharge, a complete response (CR) was achieved upon evaluation.

 

🌞Professor Wang Wei, drawing on clinical expertise, emphasized that:

TP53-mutated patients often exhibit limited response to conventional frontline treatments, making CAR-T therapy a potential benefit.

 

🌞For high-risk patients, especially those with dual expression and recurrence within 12 months, CAR-T therapy as a second-line treatment may yield benefits.

Post-CAR-T hematopoietic suppression, while common, requires nuanced management based on various factors. R-CHOP shows safety and efficacy in R/R DLBCL. Post-CAR-T bone marrow suppression is influenced by factors like prior chemotherapy lines, occurrence of CRS/ICANs, necessitating comprehensive clinical assessment and supportive care.

 

🌞In summary, CAR-T therapy presents a promising avenue for patients facing challenging lymphoma scenarios. The successful case of Mr. Li underscores the potential efficacy and safety of this innovative treatment at Peking Union Medical College Hospital.

 

#CART #Success #LymphomaTreatment #MedicalAdvancements #pekingunion #Chinesecart

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

Beacon of Hope in Cancer Treatment – What is the treatment process for CAR-T cell therapy?

Beacon of Hope in Cancer Treatment

😊😊😊 What is the treatment process for CAR-T cell therapy?

CAR-T cell therapy has emerged as a global miracle in cancer treatment, capturing widespread attention. By loading CAR onto T cells, these “super soldiers” can specifically identify and efficiently eliminate tumor cells, offering a fresh perspective for cancer patients.

 

Treatment Procedure:

💙Assessment: Doctors first evaluate whether the patient is suitable for CAR-T therapy, ensuring maximum benefit.

❤️Isolation and Sampling: T cells are extracted from peripheral blood, preparing for subsequent modifications.

💛Cell Modification: T cells are activated and modified in vitro, using biotechnological techniques to load the CAR structure for specific tumor cell recognition.

🧡Ex Vivo Expansion: Depending on the patient’s weight and treatment period, CAR-T cells are significantly expanded ex vivo to ensure an adequate quantity for treatment.

💚Infusion into the Body: The expanded CAR-T cells are reintroduced into the patient’s body, allowing the “super soldiers” to combat tumors.

💜Subsequent Monitoring: Close monitoring of the treatment’s effectiveness post CAR-T cell infusion, promptly addressing any adverse reactions to ensure optimal patient outcomes.

The advent of CAR-T cell therapy brings a new dawn for cancer patients, with its unique treatment mechanism and remarkable effects positioning it as a leader in the field of cancer immunotherapy. This scientific marvel is spreading hope globally, opening a gateway to recovery for cancer patients.

 

#CARTCellTherapy #CancerTreatment #HopeInScience #CART #Cancer #Whatiscancer #cancerpatient

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China

A Miraculous Journey: Israeli Artist Finds Cure for Multiple Myeloma in Hangzhou China

    In a remarkable medical story, we turn our attention to the experiences of a friend seeking treatment in Hangzhou China. Tali, a well-known artist from Israel. In 2012, she was diagnosed with multiple myeloma, a malignant blood disease, and after seeking treatment in various European countries, including Israel and France, she found no definitive cure. In a moment of despair, she discovered a solution from Hangzhou, China, through the European Bone Marrow Transplant Association.

    On October 6th, Tali and her family boarded a flight from Israel to Hangzhou. Under the meticulous care of Professor Huang He and his team at Zhejiang University’s First Hospital, Tali underwent over a month of intensive treatment. Today, Tali is finally on the road to recovery, expressing her gratitude to the medical staff through her preferred medium – art.

    In the hospital room, Tali and Professor Huang He share laughs and conversations. The weather looks promising, initially being skeptical about her health when arriving in Hangzhou, encouragement from the medical team reignited her hope for recovery. Using her artistic language, she documented every moment of the treatment process.

After undergoing treatment, the excruciating bone pain gradually lessened, indicating a positive turn in her health.

    “I can feel my body improving bit by bit. Green cells are gradually replacing the red ones, and my bone pain has completely disappeared. There are no tumor cells in the bone marrow anymore – they have vanished entirely.” Tali expressed.

    The advanced treatment utilized at Zhejiang University’s First Hospital involves cutting-edge blood cell separation technology. Lymphocytes are extracted and genetically engineered to attack malignant tumor cells, successfully curing multiple myeloma. This revolutionary technique is known as CAR-T cell therapy. Zhejiang University’s First Hospital stands out as one of the earliest and most experienced clinical research centers using this technology, making it a pioneer in the field.

    In here we bring you this inspiring story from Hangzhou, where art, science, and the human spirit come together in a tale of triumph over adversity.

#HangzhouMedicalMiracle #CARTCellTherapy #InspiringStories #MedicalAdvancements

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

11 months ago CAR-T

Breakthrough Ultra CAR-T Therapy Shows High Disease Control Rate of 85.7% in Advanced Platinum-Resistant Ovarian Cancer

Breakthrough Ultra CAR-T Therapy Shows High Disease Control Rate of 85.7% in Advanced Platinum-Resistant Ovarian Cancer

As a skilled overseas social media writer, here’s a revamped article for international media promotion:

 

In a groundbreaking development, PRGN-3005, an Ultra CAR-T cell therapy, is making waves with an impressive disease control rate (DCR) of 85.7% in the treatment of advanced platinum-resistant ovarian cancer. Utilizing non-viral gene delivery technology, this therapy eliminates the need for ex vivo expansion, significantly reducing production time and costs. The ability to administer the treatment rapidly, as soon as the second day after non-viral gene transfer, not only lowers production time and costs but also enhances tumor targeting precision. This holds the potential to disrupt the current landscape of CAR-T cell therapy.

 

Published in the Journal of Clinical Oncology, the “Phase 1/1b Clinical Trial of PRGN-3005 in Recurrent or Refractory (r/r) Ovarian Cancer” reported promising outcomes. The study included 25 assessable patients with a median age of 64 (range: 38-76) who had undergone extensive pretreatment with a median of 8 prior therapeutic regimens. The patients were divided into three groups: intraperitoneal (IP) infusion (C1, n = 12), intravenous (IV) infusion (C2, n = 6), and intravenous cyclophosphamide low dose (IV LD, n = 7).

 

Post-treatment, 20% of all participants exhibited regression in at least one target lesion (evaluated by RECIST 1.1 criteria). Notably, the DCR for the IV LD group was an impressive 85.7%, with a 57% reduction in target tumor burden and an average 27.4% decrease in CA125. A patient in the IV LD group experienced a 28% reduction in target tumor burden after a second PRGN-3005 infusion at the 12-month mark. Importantly, no PRGN-3005-related dose-limiting toxicities, neurotoxicities, or ≥3-grade cytokine release syndrome (CRS) adverse reactions were observed.

 

These results underscore the favorable tolerability of PRGN-3005 Ultra CAR-T therapy in treating ovarian cancer, demonstrating an encouraging disease control rate (DCR) and an overall reduction in tumor burden.

 

While CAR-T therapy has shown great promise in treating hematologic malignancies and several products have been approved, its application in solid tumor treatment is still in the clinical experimental stage. Nevertheless, with the continuous evolution of CAR-T generations, the emergence of more prominent targets, and improvements in proliferation and cytokine release aspects, the conquest of advanced solid tumors by CAR-T therapy seems imminent. Numerous clinical trials are already underway, offering hope for complete remission in fortunate patients.

 

#PRGN3005 #CARTTherapy #OvarianCancer #MedicalBreakthrough #CancerTreatment #Ovarian

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

12 months ago CAR-T

Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy

“Clinical Breakthrough: Chinese CAR-T – Inaticabtagene Autoleucel Revolutionizing Hematologic Cancer Therapy”

On January 5, 2024, the Fourth Chinese Hematology Development Conference was convened in Tianjin, China, concurrently hosting the CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS). The focus was directed towards the latest advancements and clinical applications of Inaticabtagene Autoleucel, presenting new pathways for standardized treatments.

 

Under the moderation of Professors Wu Depei and Hu Yu, Professor Wang Ying from the Institute of Hematology at the Chinese Academy of Medical Sciences presented a specialized lecture titled “Interpreting Key Clinical Data of Inaticabtagene Autoleucel.” Professor Wang highlighted the challenges faced by adult B-ALL patients in China, commonly treated with salvage chemotherapy ± hematopoietic stem cell transplantation. However, the median survival period is only 2-6 months, and targeted therapies yield a median survival of merely 7.7 months, necessitating an urgent need for more effective treatment methods. Recently, the Inaticabtagene Autoleucel infusion has been approved for treating adult R/R B-ALL patients.

 

Critical clinical research (NCT04684147) has revealed the substantial outcomes achieved with a single treatment of Inaticabtagene Autoleucel:

 

Rapid and profound remission: Within 3 months of treatment, the overall response rate (ORR) reached an impressive 82.1%, with a 100% negativity rate for minimal residual disease (MRD), showcasing the remarkable effects of Inaticabtagene Autoleucel within a short span.

 

Enduring remission: The 3-month post-treatment overall remission rate stood at 64.1%, with a 12-month sustained remission rate (DOR) of 80%. With a median follow-up of 8.0 months, the median relapse-free survival (RFS) period has not been reached. The one-year survival rates for overall infused patients, those achieving complete response (CR)/complete response with incomplete hematological recovery (CRi) within 3 months, and those reaching CR/CRi at 3 months were 67.9%, 72.0%, and 85.6%, respectively.

 

Good safety profile: The incidence rate of ≥3-grade cytokine release syndrome (CRS) was only 10.3%, and that of ≥3-grade immune effector cell-associated neurotoxicity syndrome (ICANS) was merely 7.7%. Moreover, patients recovered post-treatment without complications.

 

Furthermore, data from over 100 patients validated the clinical efficacy and safety of Inaticabtagene Autoleucel, affirming its robustness and offering renewed hope to a larger patient population. This breakthrough treatment provides a new avenue for tackling challenging diseases and is poised to revolutionize the landscape of hematologic cancer therapy.

 

#CARTRevolution #InaticabtageneAutoleucel #HematologicCancerTherapy #ClinicalBreakthrough #ChinaHematologyConference #JCIS #BAllTreatment #MedicalAdvancements #CancerResearch #TreatmentInnovation #InaticabtageneAutoleucel #Autoleucel #ChineseCART #CARTTherapy #cancer #Bloodcancer #MedicineinCHINA #Medicaltourismo #Advancedmedicine #cancertherapy

• 1
• 2
• 3